We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Masimo (MASI): Can Its 34.2% Jump Turn into More Strength?
Read MoreHide Full Article
Masimo (MASI - Free Report) shares soared 34.2% in the last trading session to close at $174.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.4% loss over the past four weeks.
The sharp rise in MASI shares can be attributed to the company’s announcement that it has entered into a definitive agreement to be acquired by Danaher Corporation in an all-cash transaction valued at $180 per share, implying a total equity value of approximately $9.9 billion. Although the transaction remains subject to regulatory approvals and other customary closing conditions, with completion expected in the second half of 2026, the clarity on valuation and strategic exit has driven strong buying interest in MASI shares.
This medical technology company is expected to post quarterly earnings of $1.43 per share in its upcoming report, which represents a year-over-year change of -20.6%. Revenues are expected to be $409.06 million, down 31.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
Masimo is part of the Zacks Medical - Instruments industry. UFP Technologies (UFPT - Free Report) , another stock in the same industry, closed the last trading session 0.1% higher at $246.13. UFPT has returned -5.7% in the past month.
For UFP, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.26. This represents a change of -8.1% from what the company reported a year ago. UFP currently has a Zacks Rank of #3 (Hold).
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Masimo (MASI): Can Its 34.2% Jump Turn into More Strength?
Masimo (MASI - Free Report) shares soared 34.2% in the last trading session to close at $174.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.4% loss over the past four weeks.
The sharp rise in MASI shares can be attributed to the company’s announcement that it has entered into a definitive agreement to be acquired by Danaher Corporation in an all-cash transaction valued at $180 per share, implying a total equity value of approximately $9.9 billion. Although the transaction remains subject to regulatory approvals and other customary closing conditions, with completion expected in the second half of 2026, the clarity on valuation and strategic exit has driven strong buying interest in MASI shares.
This medical technology company is expected to post quarterly earnings of $1.43 per share in its upcoming report, which represents a year-over-year change of -20.6%. Revenues are expected to be $409.06 million, down 31.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Masimo, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on MASI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Masimo is part of the Zacks Medical - Instruments industry. UFP Technologies (UFPT - Free Report) , another stock in the same industry, closed the last trading session 0.1% higher at $246.13. UFPT has returned -5.7% in the past month.
For UFP, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $2.26. This represents a change of -8.1% from what the company reported a year ago. UFP currently has a Zacks Rank of #3 (Hold).